Priscila Sutto-Ortiz

Dr. Priscila Sutto-Ortiz

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Cell
Verified
Journal Article
Closed access
MGMorgan S.A. Gilman
Morgan S.A. Gilman
CLCheng Liu
Cheng Liu
AFAmy Fung
Amy Fung
IBIshani Behera
Ishani Behera
PJPaul Jordan
Paul Jordan
JMJason McLellan
Jason McLellan

19 April 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RARostom Ahmed-Belkacem
Rostom Ahmed-Belkacem
MHMarcel Hausdorff
Marcel Hausdorff
ADAdrien Delpal
Adrien Delpal
PSPriscila Sutto-Ortiz
Priscila Sutto-Ortiz
ACAgathe Colmant
Agathe Colmant
FDFrançoise Debart
Françoise Debart

25 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
PSPriscila Sutto-Ortiz
Priscila Sutto-Ortiz
JEJean Eleouet
Jean Eleouet
FFFrançois Ferron
François Ferron
EDEtienne Decroly
Etienne Decroly
The human respiratory syncytial virus (RSV) is a negative-sense, single-stranded RNA virus. It is the major cause of severe acute lower respiratory tract infection in infants, the elderly population, and immunocompromised individuals. There is still no approved vaccine or antiviral treatment against RSV disease, but new monoclonal prophylactic antibodies are yet to be commercialized, and clinical trials are in progress. Hence, urgent efforts are needed to develop efficient therapeutic treatments. RSV RNA synthesis comprises viral transcription and replication that are catalyzed by the large protein (L) in coordination with the phosphoprotein polymerase cofactor (P), the nucleoprotein (N), and the M2-1 transcription factor. The replication/transcription is orchestrated by the L protein, which contains three conserved enzymatic domains: the RNA-dependent RNA polymerase (RdRp), the polyribonucleotidyl transferase (PRNTase or capping), and the methyltransferase (MTase) domain. These activities are essential for the RSV replicative cycle and are thus considered as attractive targets for the development of therapeutic agents. In this review, we summarize recent findings about RSV L domains structure that highlight how the enzymatic activities of RSV L domains are interconnected, discuss the most relevant and recent antivirals developments that target the replication/transcription complex, and conclude with a perspective on identified knowledge gaps that enable new research directions.

6 May 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
PSPriscila Sutto-Ortiz
Priscila Sutto-Ortiz
STSergey Tcherniuk
Sergey Tcherniuk
NYNina Ysebaert
Nina Ysebaert
PAPravien Abeywickrema
Pravien Abeywickrema
MNMathieu Noël
Mathieu Noël
EDEtienne Decroly
Etienne Decroly
Respiratory syncytial virus (RSV) is a negative sense single-stranded RNA virus and one of the main causes of severe lower respiratory tract infections in infants and young children. RSV RNA replication/transcription and capping are ensured by the viral Large (L) protein. The L protein contains a polymerase domain associated with a polyribonucleotidyl transferase domain in its N-terminus, and a methyltransferase (MTase) domain followed by the C-terminal domain (CTD) enriched in basic amino acids at its C-terminus. The MTase-CTD of Mononegavirales forms a clamp to accommodate RNA that is subsequently methylated on the cap structure and depending on the virus, on internal positions. These enzymatic activities are essential for efficient viral mRNA translation into proteins, and to prevent the recognition of uncapped viral RNA by innate immunity sensors. In this work, we demonstrated that the MTase-CTD of RSV, as well as the full-length L protein in complex with phosphoprotein (P), catalyzes the N7- and 2’-O-methylation of the cap structure of a short RNA sequence that corresponds to the 5’ end of viral mRNA. Using different experimental systems, we showed that the RSV MTase-CTD methylates the cap structure with a preference for N7-methylation as first reaction. However, we did not observe cap-independent internal methylation, as recently evidenced for the Ebola virus MTase. We also found that at μM concentrations, sinefungin, a S-adenosylmethionine analogue, inhibits the MTase activity of the RSV L protein and of the MTase-CTD domain. Altogether, these results suggest that the RSV MTase domain specifically recognizes viral RNA decorated by a cap structure and catalyzes its methylation, which is required for translation and innate immune system subversion.

9 March 2023 in Antiviral Research
Verified
Journal Article
Closed access
MFMikael Feracci
Mikael Feracci
CECécilia Eydoux
Cécilia Eydoux
VFVéronique Fattorini
Véronique Fattorini
LBLea Lo Bello
Lea Lo Bello
PGPierre Gauffre
Pierre Gauffre
BCBruno Canard
Bruno Canard

19 May 2024 in Antiviral Research
Verified
Journal Article
Open access
BBBrecht Bonneux
Brecht Bonneux
ASAfzaal Shareef
Afzaal Shareef
STSergey Tcherniuk
Sergey Tcherniuk
BABrandon Anson
Brandon Anson
SBSuzanne de Bruyn
Suzanne de Bruyn
FHFlorence Herschke
Florence Herschke
Respiratory syncytial virus (RSV) can cause pulmonary complications in infants, elderly and immunocompromised patients. While two vaccines and two prophylactic monoclonal antibodies are now available, treatment options are still needed. JNJ-7184 is a non-nucleoside inhibitor of the RSV-Large (L) polymerase, displaying potent inhibition of both RSV-A and -B strains. Resistance selection and hydrogen-deuterium exchange experiments suggest JNJ-7184 binds RSV-L in the connector domain. JNJ-7184 prevents RSV replication and transcription by inhibiting initiation or early elongation. JNJ-7184 is effective in air-liquid interface cultures and therapeutically in neonatal lambs, acting to drastically reverse the appearance of lung pathology.